Latest news with #CSL
News.com.au
6 hours ago
- Business
- News.com.au
‘Downplayed unemployment shock': Market drops on RBA governors speech
Australia's sharemarket slid during Thursday's trading as disappointing quarterly updates and a speech by Reserve Bank governor Michele Bullock weighed on the market. The benchmark ASX 200 closed lower on Thursday dropping 27.80 points or 0.32 per cent to 8,709.40 points while the broader All Ordinaries slipped 22 points or 02.4 per cent to 8,979.40. The Aussie dollar jumped 0.19 per cent and is now buying 66.11 US cents. All sectors except health care closed in the red, with the falls led by industrials, property, consumer discretionary and energy stocks. Market heavyweight CSL gained 1.53 per cent to $269.56, while ResMed gained 0.44 per cent to $41.10 and Cochlear closed 0.03 per cent higher to $314.01. Three of the four major banks also finished in the green, despite the sector as a whole falling. CBA eked out a 0.10 per cent gain to $173.47, NAB jumped 1.24 per cent to $37.66 and Westpac finished 0.54 per cent higher to $33.29. ANZ was the outlier sliding 0.43 per cent to $30.44. After jumping on the opening bell, shares subsequently fell after RBA governor Michele Bullock made her speech at the Annika Foundation lunch. IG market analyst Tony Sycamore said the market's confidence in a rate cut in August slipped after the speech. 'The RBA governor has elected to look through the recent criticism and, in her speech, downplayed the rise in employment saying it wasn't a surprise,' he wrote in a market note. 'She also noted that monthly inflation data suggests the inflation rate may not fall as fast as forecast in May.' Following Ms Bullock's speech the markets knocked off about five basis points or RBA rate cuts by the end of the year. In company news earnings results disappointed on Thursday. Macquarie shares dived 5.08 per cent to $213.84 after telling the market longstanding chief financial officer Alex Harvey will retire mid-2026 as well as announcing its first quarter data. Macquarie, which is broken up into four business segments, said its banking and financial services and Macquarie capital improved performance over the three months until June 30. But its Macquarie Asset Management and Commodities and Global Markets segments slipped. Overall Macquarie Group reported a $3.7bn profit for FY25. It was also a disappointing trading update for Bapcor with shares slumping to a five-year low after the Autobarn and Midas owner said statutory net profits after tax would lie between $31 to $34m. Shares in the company slumped 28.38 per cent to $3.66 on the announcement. In a positive trading update Fortescue shares jumped 4.34 per cent to $19 after the investing giant announced its fourth quarter update showing it shipped a record-breaking annual shipment of 198.4Mt in FY 2025. Lynas Rare Earths gained 5.03 per cent to $10.65 after its shipment jumped 38 per cent compared to the prior quarter.
Top Gear
7 hours ago
- Automotive
- Top Gear
Meet your heroes: is the BMW M3 CSL still a performance car great in 2025?
Retro That noise. Those looks. That classic video. Top Gear meets a legend to see if it lives up to the hype Skip 5 photos in the image carousel and continue reading The night before I finally drove the most fawned over and respected M3 of all time, I relived the moment I became infatuated with it. This 'moment' is 10 minutes and 34 seconds long, and a kindly pirate has lobbed it onto YouTube. It's a review of a 110kg lighter 'superfast' version of the BMW M3 from 2 November 2003, from a BBC motoring show called Top Gear. I was 12, so Jeremy's jibes about unnecessary traction control and the legality of semi-slick tyres flew over my head. Two things stuck to me. First, the location. The test was shot on the Isle of Man, as Clarkson drew an allegory between the island's Blair-defying, speed limit-shunning rejection of bureaucracy and the hardcore CSL's two-fingered salute to the nanny state. Advertisement - Page continues below Second? The noise. That razor-edged metallic bark of induction roar that sounded as if you were watching the whole thing unfold from inside the 3.2-litre straight six's carbon fibre air box. Photography: Olgun Kordal You might like I've waited 22 years for today. You barely ever see a CSL on the road: only 1,383 were ever made and they're now deemed too valuable to be risked on the public highway or the track days they were bred for. I've never sat in one, never even fogged up the glass peering within and wondering what it'd be like to nestle in that bucket seat. Hold on to that thick suede steering wheel. Maybe even drive it. This isn't the Isle of Man. But Exmoor is doing a convincing impression of a rock in the Irish sea today – it's gusty with lashings of rain and 100 per cent cloud cover at a height of three feet. The CSL arrives on a transporter, running late because the truck driver thought there'd been some kind of administrative error. 'He wants the one with no tyre tread? The really rare one? In this? Are you sure?' Advertisement - Page continues below As it rolls off the truck it's striking that the CSL... isn't. In 2003 this hunkered-down, carbon-roofed coupe was the most butch Beemer ever. Compared to today's beavertooth M3 and the unutterable horror of the iX and XM, the elegant E46 shape is so classy, adorned with CSL upgrades only true M people spot. Asymmetric bumper porthole, that ducktail, those Y-spoke rims. I'm stalling because there's a chance this day could become a disappointment – 355bhp is today's hot hatch territory. Time has not been kind to the early 2000's obsession with semi-automated flappy paddle gearboxes – the uncanny valley of lightning shift transmissions before dual clutchers revolutionised cog swapping. There's now a buoyant trade in actually swapping BMW's clunky SMG box out for a traditional manual. It feels narrow, and responsive in a way a modern M car, even with all that tech, can't fake I wouldn't. Partly because it's such a crucial part of the CSL's character – you have to drive it with consideration, lifting the throttle for each upshift. And partly because the CSL is the bridge between BMW glory days of old and the genesis of the modern configurable M car – all choices, modes and settings. This was the first M to offer switchable shift speeds. Dial it up to the max, then blip the pedal as the needle passes the warm orange lights at the screaming 7,900rpm red line. Yep. It's exactly as joyously raw, flawed and rewarding as I wanted it to be. Thank you for subscribing to our newsletter. Look out for your regular round-up of news, reviews and offers in your inbox. Get all the latest news, reviews and exclusives, direct to your inbox. What was in 2003 a rock hard road racer is today leany through turns. But it feels narrow, and responsive in a way a modern M car, even with all that tech, can't fake. It's wearing the modern successor to the infamous near slick Michelin Pilot Sport Cups it was sold on, so sploshing down the B3223 still presents an ever present aquaplane danger, but I've seen, heard and felt enough to know this is still an all time great street car. With prices now firmly in 'POA' nonsense territory, today's washout is probably my only chance to bond with a CSL. Still, there's always a set of headphones and YouTube...
&w=3840&q=100)
Business Standard
20 hours ago
- Health
- Business Standard
US bans flu shots with thimerosal in RFK Jr led vaccine policy shift
The United States will stop distributing all influenza vaccines that contain mercury-based preservative thimerosal, marking the latest move by US Health Secretary Robert F. Kennedy Jr. to reshape vaccine policy. Last month, a vaccine panel with members handpicked by Kennedy voted in favor of Americans receiving seasonal flu shots that are free from thimerosal, despite decades of studies showing no related safety issues. About 5 per cent of flu shots given in the US in the last flu season were multi-dose vials that contained the preservative, which was largely phased out decades ago. Anti-vaccine groups have for decades linked thimerosal to autism and other neurodevelopmental disorders, and Kennedy wrote a book in 2014 in which he advocated for "the immediate removal of mercury" from vaccines. The FDA on its website says "there was no evidence that thimerosal in vaccines was dangerous," and that the decision to remove it previously was a precautionary measure to decrease overall exposure to mercury among young infants. One of the panelists, who voted against the recommendation, had pointed out that the risk of not receiving the influenza vaccine because it contains thimerosal is greater than any known risks of the preservative. CSL's Afluria, and Flucelvax and Sanofi's Fluzone include thimerosal in multi-dose versions, according to the FDA's website. Kennedy accepted the panel's recommendation, the Department of Health and Human Services said on Wednesday, in the absence of the CDC director, who typically signs off on them before they are implemented. President Donald Trump's nominee for the CDC director, Susan Monarez, is yet to be confirmed by the US Senate. Other recommendations made by the panel, known as the Advisory Committee for Immunization Practices, at a meeting in June are still under review, the HHS said. Vaccine manufacturers have confirmed that they have the capacity to replace multi-dose vials containing the preservative, ensuring that supplies will not be interrupted, HHS said. Sanofi said it acknowledges the new policy and will have sufficient supply of the flu vaccine this season. CSL did not immediately respond to a Reuters request for comment.
Reuters
21 hours ago
- Health
- Reuters
US ends use of flu shots with thimerosal in latest move by health secretary Kennedy
July 23 (Reuters) - The United States will stop distributing all influenza vaccines that contain mercury-based preservative thimerosal, marking the latest move by U.S. Health Secretary Robert F. Kennedy Jr. to reshape vaccine policy. Last month, a vaccine panel with members handpicked by Kennedy voted in favor of Americans receiving seasonal flu shots that are free from thimerosal, despite decades of studies showing no related safety issues. About 5% of flu shots given in the U.S. in the last flu season were multi-dose vials that contained the preservative, which was largely phased out decades ago. Anti-vaccine groups have for decades linked thimerosal to autism and other neurodevelopmental disorders, and Kennedy wrote a book in 2014 in which he advocated for "the immediate removal of mercury" from vaccines. The FDA on its website says "there was no evidence that thimerosal in vaccines was dangerous," and that the decision to remove it previously was a precautionary measure to decrease overall exposure to mercury among young infants. One of the panelists, who voted against the recommendation, had pointed out that the risk of not receiving the influenza vaccine because it contains thimerosal is greater than any known risks of the preservative. CSL's ( opens new tab Afluria, and Flucelvax and Sanofi's ( opens new tab Fluzone include thimerosal in multi-dose versions, according to the FDA's website. Kennedy accepted the panel's recommendation, the Department of Health and Human Services said on Wednesday, in the absence of the CDC director, who typically signs off on them before they are implemented. President Donald Trump's nominee for the CDC director, Susan Monarez, is yet to be confirmed by the U.S. Senate. Other recommendations made by the panel, known as the Advisory Committee for Immunization Practices, at a meeting in June are still under review, the HHS said. Vaccine manufacturers have confirmed that they have the capacity to replace multi-dose vials containing the preservative, ensuring that supplies will not be interrupted, HHS said. Sanofi said it acknowledges the new policy and will have sufficient supply of the flu vaccine this season. CSL did not immediately respond to a Reuters request for comment.
AU Financial Review
a day ago
- Business
- AU Financial Review
Why clinical labs are hot property for asset managers
Property developers are circling prime sites being rezoned for high-density development to tackle the housing shortage on Sydney's north shore. However, the demand for apartments has been superseded by a different type of tenant on one key site. Laboratory space for hundreds of scientists working for biotechs and other life science start-ups – which hope to become the next Cochlear or CSL – is in short supply.
